ArticleFrontiers in immunology2026
Integrating genomic structural equation modeling and experimental validation to unravel the genetic basis of male genital lichen sclerosus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the genetic architecture of male genital lichen sclerosus (MGLSc) and to identify potential susceptibility loci, candidate genes, and biological pathways associated with disease pathogenesis by integrating genomic structural equation modeling (Genomic-SEM) with multi-omics analyses and experimental validation. Methods: Publicly available genome-wide association study (GWAS) summary statistics of MGLSc-related traits were integrated to construct a Genomic-SEM framework. Linkage disequilibrium score regression (LDSC) was used to estimate genetic correlations and evaluate model stability. Functional mapping and annotation were performed using FUMA, and novel loci were further screened through a GWAS subtraction strategy. Fine-mapping was conducted using SuSIE and FINEMAP to prioritize candidate causal variants. Transcriptome-wide association study (TWAS) and FOCUS were applied to identify candidate genes. MAGMA-based gene enrichment, partitioned heritability analysis, and polygenic risk score (PRS) analyses were further performed to characterize the biological relevance of associated loci. Finally, RT-qPCR was conducted Results: The Genomic-SEM showed a good overall fit and generated an indirect GWAS framework comprising 2,451,318 SNPs for MGLSc. A total of 208 SNPs reached conventional genome-wide significance, and FUMA annotation identified 43 risk loci, 52 lead SNPs, and 14 candidate genes. Using the GWAS subtraction strategy, 13 novel SNPs were further identified, including rs715299 and rs10774625. Fine-mapping highlighted four high-confidence variants, namely rs3134608, rs3134952, rs3763307, and rs2076524, mainly clustered in the chromosome 6 major histocompatibility complex region. TWAS identified HLA-DPA1 as the most significant gene, and FOCUS further supported its likely causal role. MAGMA and enrichment analyses suggested that immune-related and regulatory regions contributed substantially to MGLSc heritability. PRS analysis demonstrated marked heterogeneity across chromosomes, with chromosome 6 showing the strongest SNP-level contribution. RT-qPCR confirmed that HLA-DPA1 expression was significantly decreased in MGLSc samples compared with controls ( Conclusion: This study provides a systematic view of the genetic basis of MGLSc by integrating Genomic-SEM, fine-mapping, transcriptomic prioritization, and experimental validation. Our findings indicate that MGLSc is influenced by a shared polygenic architecture enriched in immune-related loci, particularly within the HLA region. HLA-DPA1 emerged as a high-confidence susceptibility gene, and multiple novel loci and candidate genes were identified, offering new insights into the molecular mechanisms underlying MGLSc and potential targets for future mechanistic and translational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.